EFM
NRIX icon

E Fund Management’s Nurix Therapeutics NRIX Stock Holding History

E Fund Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$291K Buy
+18,796
New +$312K 0.01% 400
2025
Q2 		– Sell
-10,288
Closed -$122K – 418
2025
Q1 		$122K Buy
+10,288
New +$172K 0.01% 377

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

E Fund Management's NRIX Position: Q1 2026 in Review

E Fund Management opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 18,796 shares worth $291K. The stake represents 0.01% of the portfolio and ranks #400 among its holdings. This is a return to the name: E Fund Management previously reported a position in NRIX as recently as Q1 2025.

E Fund Management first reported a position in NRIX in Q1 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • E Fund Management held 18,796 shares of Nurix Therapeutics worth $291K as of Q1 2026.
  • Nurix Therapeutics was a new E Fund Management position in Q1 2026.
  • Nurix Therapeutics made up 0.01% of E Fund Management's portfolio in Q1 2026, its #400 holding.
  • E Fund Management first reported a position in Nurix Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.